...By BioCentury Staff After two decades at Alkermes plc (NASDAQ:ALKS), James Frates will join neurodegenerative diseases company Amylyx Pharmaceuticals Inc... ...in 2019, helped raise millions of dollars to fight the disease via the Ice Bucket Challenge. Alkermes...
...By Jeff Cranmer, Executive Editor As James Frates prepares to depart Alkermes after two decades, the... ...unveiled in December in the wake of discussions with activist investor Elliott Advisors.Frates, who joined Alkermes plc... ...a six-year stint at San Francisco wealth management firm Robertson Stephens, will pursue another opportunity. Alkermes...
...Audentes Therapeutics Inc., an Astellas Pharma Inc. (Tokyo:4503) company, is in development for X-linked myotubular myopathy.Alkermes’... ...3831 returns to FDA for review FDA has accepted an NDA resubmission for ALKS 3831 from Alkermes plc...
...Partners Acquisition Corp. (NASDAQ:BRPA), a special purpose acquisition company. SPACs re-emerged this year as a viable IPO alternative.Alkermes... ...Healthcare Fund
Zheshang Innovest
HighTide Therapeutics Inc.
Greater Bay Area Homeland Development Fund
Hangzhou Tigermed Consulting Co. Ltd.
Citic Securities
NeuroRx Inc.
Alkermes plc
China...
...By Paul Bonanos, Associate Editor Alkermes expects a swift resolution to a manufacturing issue that led... ...3831, but the company isn’t yet committing to a launch timeline for the antipsychotic combination therapy.Alkermes plc... ...buprenorphine.Alkermes closed up $0.45 to $18.30 on Tuesday.TARGETSMOR (OPRM1) - μ opioid receptor
Paul Bonanos
samidorphan/olanzapine (ALKS 3831)
Alkermes plc...
...rights via its $915 million takeout of Dova Pharmaceuticals Inc. last year. FDA panel: labeling sufficient to mitigate Alkermes... ...associated with opioid antagonist action of samidorphan, one of the components of ALKS 3831 from Alkermes plc...
...CartaNA AB, which is developing in situ RNA analysis technology. FDA to discuss safety, efficacy of Alkermes’... ...disorder candidateBriefing documents released ahead of Friday’s FDA advisory committee meeting to discuss olanzapine/samidorphan from Alkermes plc...
...By BioCentury Staff After two decades at Alkermes plc (NASDAQ:ALKS), James Frates will join neurodegenerative diseases company Amylyx Pharmaceuticals Inc... ...in 2019, helped raise millions of dollars to fight the disease via the Ice Bucket Challenge. Alkermes...
...By Jeff Cranmer, Executive Editor As James Frates prepares to depart Alkermes after two decades, the... ...unveiled in December in the wake of discussions with activist investor Elliott Advisors.Frates, who joined Alkermes plc... ...a six-year stint at San Francisco wealth management firm Robertson Stephens, will pursue another opportunity. Alkermes...
...Audentes Therapeutics Inc., an Astellas Pharma Inc. (Tokyo:4503) company, is in development for X-linked myotubular myopathy.Alkermes’... ...3831 returns to FDA for review FDA has accepted an NDA resubmission for ALKS 3831 from Alkermes plc...
...Partners Acquisition Corp. (NASDAQ:BRPA), a special purpose acquisition company. SPACs re-emerged this year as a viable IPO alternative.Alkermes... ...Healthcare Fund
Zheshang Innovest
HighTide Therapeutics Inc.
Greater Bay Area Homeland Development Fund
Hangzhou Tigermed Consulting Co. Ltd.
Citic Securities
NeuroRx Inc.
Alkermes plc
China...
...By Paul Bonanos, Associate Editor Alkermes expects a swift resolution to a manufacturing issue that led... ...3831, but the company isn’t yet committing to a launch timeline for the antipsychotic combination therapy.Alkermes plc... ...buprenorphine.Alkermes closed up $0.45 to $18.30 on Tuesday.TARGETSMOR (OPRM1) - μ opioid receptor
Paul Bonanos
samidorphan/olanzapine (ALKS 3831)
Alkermes plc...
...rights via its $915 million takeout of Dova Pharmaceuticals Inc. last year. FDA panel: labeling sufficient to mitigate Alkermes... ...associated with opioid antagonist action of samidorphan, one of the components of ALKS 3831 from Alkermes plc...
...CartaNA AB, which is developing in situ RNA analysis technology. FDA to discuss safety, efficacy of Alkermes’... ...disorder candidateBriefing documents released ahead of Friday’s FDA advisory committee meeting to discuss olanzapine/samidorphan from Alkermes plc...
